Product Images Donepezil Hydrochloride

The text describes a clinical study, presenting a chart or graph (Figure 1) of the time-course of the change from baseline in ADAS-cog (a cognitive assessment tool) score for patients who completed 24 weeks of treatment. The study compares the effects of Donepezil Hydrochloride Tablets (5mg/day) to a Placebo. The rest of the text is illegible due to errors.*

This is a description of a study of Donepezil Hydrochloride Tablets conducted over 24 weeks with three different treatment groups: a 5 mg/day group, a 10mg/day group, and a placebo group. The results display the change in ADAS-cog scores from baseline and the cumulative percentage of patients completing the study with specified changes from baseline ADAS-cog scores. The study had a completion rate of 80% for the placebo group, 85% for the 5 mg/day group, and 68% for the 10mg/day group.*

This appears to be a report or study evaluating the efficacy of Donepezil Hydrachloride Tablets at a dosage of 10 mg per day. The table shows the results of the CIBIC-plus rating system at week 24, with a frequency distribution of scores for patients. The table also includes a placebo group. The text does not provide any additional information about the study or its findings.*

This text describes a study where patients completed a 15-week treatment for a condition. The treatment was either a drug or a placebo. The time-course of change from baseline in ADAS-cog score was recorded in the study. There are some numbers and symbols but not enough context to derive any meaningful interpretation from them.*

This appears to be a table or chart showing the effects of Donepezil Hydrochloride Tablets on patients with ADAS-cog scores. The table displays the treatment group, the percentage of patients who experienced a change in ADAS-cog score, and the dosage (5mg or 10mg). The chart shows the percentage of patients with specified changes in ADAS-cog scores from the baseline with a line graph. The study had a completion rate of 93% for the placebo group, 90% for the 5mg/day group, and 82% for the 10mg/day group.*

The text describes a clinical study of the efficacy of two Donepezil Hydrochloride dosage amounts and a placebo in improving patients' condition over a 12-week period. The results are presented in a graph that shows the frequency distribution of CIBIC-plus scores. The text does not provide enough information to ascertain the specific results of the study.*

This is a graph showing the time course of change in SIB score for patients who completed three months of treatment with Donepezil Hydrochloride Tablets 10mg/day and Placebo. The graph shows improvement in scores for patients who received Donepezil Hydrochloride Tablets and decline for those who received Placebo.*

The text describes a figure labeled "Figure 8" which shows the time course of change from baseline in ADCS-ADL-Severe score for patients completing 6 months of treatment. The figure displays data related to clinical improvement and clinical decline, with corresponding values on the y-axis ranging from -4 to 4. The x-axis displays the duration of 6 months of drug treatment.*

Donepezil HCI is a medication administered via 5mg tablets manufactured and packaged by Torrent Pharmaceuticals. These 30 tablets should be taken as directed by a doctor and are Rx only. The pills are film-coated and are usually prescribed for specific conditions which can be found in the accompanying prescribing information. This lot number is a sample, and the expiration date is 10/04/12. The CPSNDC number for these tablets is 67046-134-30. Store the medication between 20-25°C (68-77°F) and excursions permitted to 15-30°C (59-86°F) [See USP Controlled Room Temperature]. The product is packaged by Coniract Pharmacy Services-PA at 125 Titus Ave, Suits #200, Warrington, PA 18976.*

This is a prescription medicine called Donepezil hydrochloride in tablet form, with each coated tablet containing 10 mg of the substance. It is packaged in a bottle of thirty tablets with a lot number and expiration date, and the prescription label should be followed for the dosage information. The medicine should be stored within the temperature range of 20-25 °C with allowed excursions between 15-30 °C, according to USP Controlled Room Temperature standards. The manufacturer is Torrent and the product is distributed by Contract Pharmacy Services-PA, located at 126 Tilus Ave, Suite #200, Warrington, PA 18976.*